🇺🇸 FDA
Pipeline program

Comparator: MK0594 5 mg/day

0594-020

Phase 2 small_molecule terminated

Quick answer

Comparator: MK0594 5 mg/day for Alcohol Dependence is a Phase 2 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
VYNE Therapeutics
Indication
Alcohol Dependence
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials